Mayne Pharma Group (OTCMKTS:MAYNF) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of branded and generic products. Headquartered in Melbourne, Australia, the company traces its origins back to the late 19th century, evolving from a regional API supplier into a global pharmaceuticals business. Over the years, Mayne Pharma has built a diversified product portfolio that spans modified-release oral dosage forms, complex injectables, and transdermal therapies, addressing therapeutic areas such as neurology, oncology and pain management.
Central to Mayne Pharma’s offering is its extended-release technology platform, which underpins products designed to improve patient compliance and deliver consistent therapeutic effect. The company’s manufacturing network includes facilities in Brisbane, Australia and Seton, Texas, where it produces a range of solid-dose and sterile injectable medicines for both its in-house pipeline and contract manufacturing clients. In addition to its own marketed brands, Mayne Pharma collaborates with biotechnology and pharmaceutical partners globally to in-license niche assets and advance late-stage pipeline candidates.
Mayne Pharma serves markets in North America, Europe, Australia and parts of Asia, leveraging a dedicated commercial organization in the United States to support branded product launches and generic product roll-outs. In recent years, the company has strengthened its position through strategic acquisitions, integrating specialized manufacturing capabilities and expanding its injectable portfolio. This global footprint enables Mayne Pharma to respond to regional regulatory requirements and meet rising demand for complex generics and specialty therapies.
The business is guided by an experienced leadership team led by CEO Mark L. Irwin, who brings more than two decades of pharmaceutical industry experience to the role. Under his direction, Mayne Pharma has prioritized investment in research and development, streamlined operations and pursued disciplined portfolio optimization. The board of directors and senior management continue to drive the company’s mission of delivering high-quality, cost-effective medicines to patients and healthcare systems worldwide.
AI Generated. May Contain Errors.
Free MAYNF Stock Alerts